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Lewy body diseaseMitochondrial dysfunction is observed in both the aging brain, and as a core feature of several neurodegenerative
diseases. A central mechanism mediating this dysfunction is acquired molecular damage to mitochondrial DNA
(mtDNA). In addition, inherited stable mtDNA variation (mitochondrial haplogroups), and inherited low level
variants (heteroplasmy) have also been associated with the development of neurodegenerative disease and pre-
mature neural aging respectively. Herein we review the evidence for both inherited and acquiredmtDNAmuta-
tions contributing to neural aging and neurodegenerative disease. This article is part of a Special Issue entitled:
Mitochondrial Dysfunction in Aging.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are critical intracellular organelles present within al-
most all eukaryotic cells in the humanbody. Their primary role is to per-
form oxidative phosphorylation generating adenosine triphosphate
(ATP), the predominant energy substrate of the cell [1].
The central pathway of oxidative phosphorylation is the mitochon-
drial respiratory chain, and many of the proteins within the chain are
encoded for by genes within mitochondrial DNA. Mitochondrial DNA,
is a 16.5 Kb circular genome, and unlike nuclear DNA, is exclusively ma-
ternally inherited. From the initial pool ofmitochondrial genomes in the
fertilized oocyte stem all subsequent copies of the mitochondrial ge-
nome. Crucially, and with particular relevance to aging processes, the
mitochondrial genome also undergoes lifelong replication, even in
post-mitotic cells (such as neurons, muscle).
It is now well recognized that in tissues including the brain, impair-
ment of mitochondrial respiratory chain function occurs with age [2,3]
suggesting that a deﬁciency of oxidative energy production may con-
tribute to the process of aging. In addition, it is now increasingly recog-
nized that mitochondria also play an important role in several other key
intracellular pathways such as calcium signaling, lipid biosynthesis and
programmed cell death (apoptosis) [4], all ofwhich are increasingly rec-
ognized as central processes in the development of several neurodegen-
erative diseases [5,6]. Taken together, impairment of mitochondrial
function is now placed at the heart of many established and emerging
theories of aging and neurodegeneration [7].ndrial Dysfunction in Aging.
dicine, UK.
.Whilst not all mitochondrial dysfunction stems from mutations in
mitochondrial DNA (mtDNA), a signiﬁcant proportion of age relatedmi-
tochondrial dysfunction is hypothesized to be due to the accumulation
of mitochondrial DNAmutations as a consequence of their ongoing rep-
lication in life. Suchmutations can be uniquewithin individual cells and
expand over time resulting in an impairment of cellular function.
In addition, recent studies have begun to change our understanding
that all of the observed mtDNA mutations in aged tissues have exclu-
sively developed in life. As we inherit several copies of themitochondri-
al genome rather than a single copy, it is now apparent that a small
number of the inherited copies may contain mutations in mtDNA
(termedheteroplasmy), and thesemutationsmay subsequently expand
during life rather and did not form de novo during life [8].
The idea that mitochondrial dysfunction in aging may, at least in
part, result from an interplay of both heritable and acquired molecular
damage to mtDNA, generates important questions regarding the role
of mtDNA mutations in aging and disease and the degree to which
these factors may be heritable and modiﬁable.
In this reviewwe describe the current evidence for the role, mecha-
nism, nature and type ofmitochondrial DNAmutations involved in neu-
rodegeneration and neural aging.
2. Mitochondrial ATP production
ATP is produced speciﬁcally by the mitochondrial respiratory chain
which consists of approximately 100 proteins clustered in speciﬁc ‘com-
plexes’ on the innermitochondrial membrane (Fig. 1). It is the interplay
between these complexes which enables ATP to be produced through
oxidative phosphorylation (OXPHOS). To initiate the process of phos-
phorylation, electrons are received from electron donors produced
Fig. 1. Themitochondrial respiratory chain. Electrons (e−) are donated by NADH and FADH2 to complex I and complex II. They then pass through co-enzyme Q (Q) onto complexes III, IV
and cytochrome c oxidase (C). These stages enable hydrogen ions to be pumped into the intermembrane space which then ﬂow back through complex IV into the mitochondrial matrix
generating ATP.
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and FAD+). Thesemolecules pass electrons to complex I and II in the re-
spiratory chain, and subsequently the electrons ﬂow on to complex III
(cytochrome B) and complex IV (cytochrome c oxidase). At each of
these steps, a small amount of energy is released which is used to
pump protons across the inner mitochondrial membrane creating an
electrochemical gradient with an excess of hydrogen ions in the inter-
membrane space. The energy stored in this electrochemical potential
is then able to ﬂow down this gradient, through complex V (ATP syn-
thase) resulting in the production of ATP from adenosine diphosphate
(ADP) and inorganic phosphate (Pi), in a phosphorylation reaction [9,
10]. The electrons reaching the end of this chain are ‘accepted’ by oxy-
gen and eventually form water (H2O).Fig. 2. Themitochondrial genome. Letters refer to the 22 tRNAs genes. The two ribosomal
RNAgenes (16S and 12S) are coded green.Genes encoding the subunits of complex I are in
light blue, cytochrome c oxidase in pink, cytochrome b of complex III in red. The subunits
of ATP synthase are in yellow. The non-coding control region (D-loop) is gray, and the or-
igins of heavy and light chain replication and transcription are labeled OH and OL
respectively.3. Mitochondrial DNA
Human mtDNA is a circular, double-stranded DNA molecule which
in humans is 16,569 base pairs in length [11]. The two strands of mito-
chondrial DNA are termed the heavy (H-strand) and light (L-strand);
the former being guanine rich and the latter cytosine rich (Fig. 2). Unlike
the nuclear genome which is only present in two copies in a post-
mitotic cell, each cell contains between 100 and 10,000 mitochondria,
with each mitochondrion containing between 2 and 10 copies of mito-
chondrial DNA [12]. The overall cellular content of mtDNA generally
correlates with the underlying energy demand of the cell.
Of the 37 genes encoded within the mitochondrial genome, 28 are
situated on the H-strand and 9 are present on the L-strand (Fig. 2).
The most common function of these genes is to encode transfer RNA
(22 genes) and polypeptide components of themitochondrial respirato-
ry chain (RC) (13 genes). Two genes encode a 16s rRNA (large ribosom-
al subunit), and one a 12s rRNA (small ribosomal subunit) [11]. Unlike
nuclear DNA in which 98–99% is non-coding [13], most mtDNA genes
are contiguous, generally separated by one or two non-coding base
pairs, resulting in approximately 93% of mtDNA bases encoding pro-
teins. The only signiﬁcant non-coding region is within the displacement
loop (D-loop)which contains the site formitochondrial DNA replication
initiation (origin of heavy strand synthesis, OH) [11]. Just as a single
human reference genome for nuclear DNA is used as a template to re-
cord and annotate genetic variation [13], so is a single mtDNA genome
(the revised Cambridge Reference Sequence (rCRS)) [11]. Geneticvariation within the mitochondrial genome is therefore generally de-
scribed with reference to this sequence.
Mitochondrial DNA also differs fromnuclear DNA in its organization.
Nuclear DNA is associated with histone complexes which are responsi-
ble for the packaging of nuclear DNA into nucleoids [14]. In comparison,
mtDNA is located on the innermitochondrial membrane and associated
with several proteins forming it's own nucleoid such as mtDNA poly-
merase gamma (encoded by POLG), mtDNA transcription initiating
factors (encoded by TFAM) together with mtDNA binding proteins and
helicases (encoded by mtSSB and twinkle) [14]. mtDNA also differs
from nuclear DNA in its base composition, encoding only two stop
codons ‘AGA’ and ‘AGG’ in comparison to 4 encoded by nDNA [15].
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Mitochondrial DNA, as discussed below, has a propensity to mutate.
This mutagenesis can lead to a range of mutations from neutral to path-
ogenic, the latter causing primary mitochondrial disease, and are
reviewed elsewhere [16,17]. Within this spectrum lie non-pathogenic
protein altering variants, and they, along with some neutral variants,
can become stable homoplasmic polymorphisms within populations,
separated by common sequence variation, and are termed haplogroups
[18,19] (Fig. 3).
The ﬁrst mtDNA haplogroups were discovered in Native Americans
and were given letters A, B, C and D [20], and subsequently all letters
of the alphabet (except O) have been designated togetherwith a variety
of sub-haplogroups [21]. In the context of neurodegeneration, several
studies have searched for an association between mtDNA haplogroups
and neurodegenerative disorders such as Parkinson's disease (PD)
[22–24], Alzheimer's disease (AD) [25–27], stroke [28], motor neuron
disease/Amyotrophic Lateral Sclerosis (ALS) [29] and Frontotemporal
dementia (FTD) [30]. These associations are discussed later.3.2. Mechanisms of somatic mtDNA mutation generation
3.2.1. Point mutations
MtDNA, like nDNA, is damaged by intracellular events such as nucle-
ases, reactive oxygen species, and spontaneous hydrolytic processes.
The single stranded nature of mtDNA replication, and lack of co-
existent histone complex proteins were hypothesized tomake it exqui-
sitely more vulnerable to such insults [31]. However, oxidative damage
as measured by 7,8-dihydro-8-oxo-deoxyguanosine (8-oxodG) pre-
dominantly induce G:C to T:A transversionmutations [32] which are in-
consistent with the pattern of transitional mutations most commonly
seen in mammalian aged brain [33]. In contrast, mice harboring muta-
tions in DNA polymerase γ (POLG) predominantly generate transitional
mutations within the germline [34,35] and somatic point mutational
spectra similar to those observed in aged human tissue [33]. TheseFig. 3. Origins of mtDNAmutations associated with aging and neurodegenerative disease. The r
vised Cambridge Reference sequence version of the mitochondrial genome. The left hand co
germline and confer varying risk for some neurodegenerative diseases (Haplogroups H, U
heteroplasmic variants and somatic DNA mutations, which can occur within any haplogroup. L
matic mtDNA deletions develop de novo (blue circle), together with expansion of the inherited
tions (black circles).data suggest that impaired replication may be the primary event in so-
matic point mutation formation rather than oxidative damage.
Until recently it was hypothesized that a contributing factor to
mtDNA point mutation generation was a relative inefﬁciency of
mtDNA maintenance. Over the last 2 decades it has however become
clear that amore complex and efﬁcient DNAmaintenance system exists
than previously suggested [36], and therefore mtDNA replication errors
remain the most likely primary mechanism inducing somatic mtDNA
point mutations.
3.2.2. Mitochondrial DNA deletions
Single strand breaks in mtDNA can occur as a result of either exoge-
nous insults such as ROS mediated damage or from aberrations in
mtDNA replication processes. They are recognized by the poly(ADP ri-
bose) polymerase (PARP) family of proteins [37], and repaired using
similar machinery and processes to base excision repair (BER) [38].
The mechanism of double strand breaks (DSBs) is far from understood,
and whilst mechanisms similar to homologous recombination (utilized
to repair DSB in nuclear DNA) are utilized to repair DSB in plants and
fungi [39], it is unclear whether these processes occur in mammalian
cells. Until recently, mis-repair of double-strand breaks were suspected
to be the cause of mtDNA deletions seen in aged human tissues [40].
More recently the detection that the majority of deletion breakpoints
occur at sites of mtDNA replication (replication forks), implies that
again, replication in conjunction with repair and recombination may
be centrally involved in their formation [41].
3.3. Homoplasmy and heteroplasmy
The term homoplasmy refers to the presence of identical copies of
mtDNA within a cell. This mtDNA genome may contain several vari-
ants compared to the rCRS such as haplogroup-associated variants
(described above). Heteroplasmy is the presence of a mixture of mu-
tant and wild-type mtDNA genomes within a cell. Through somatic
mutagenesis, and ongoing replication of mtDNA, mutations can clon-
ally expand through either random drift or selective processes, andeference mitochondrial genome is positioned center-top labeled rCRS to represent the re-
lumn represents the different homoplasmic haplogroup variants which exist within the
and J labeled for illustrative purposes). The right column represents the generation of
ow-level heteroplasmic variants (red circle) are inherited in the germline. With time, so-
rare heteroplasmic variants (red circles), and somatic generation of differing point muta-
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with cells [42].
Recently there has been a shift in our understanding of heteroplasmy.
Using next generation sequencing techniques, universal mtDNA
heteroplasmy has been detected in human tissues [43]. This suggests
that mutations previously attributed as being somatically generated,
and therefore occurring de novo within the brain and other tissues,
may actually be clonal expansion of the inherited low level hetero-
plasmic variants not visible with previous sequencing technologies
[43,8,44]. Determining whether similar mechanisms occur in brain
is of paramount importance given the ﬁnding in POLG mutant mice
that low-level inherited heteroplasmic variants can clonally expand
over subsequent generations aggravating aging and inducing
neurodevelopmental abnormalities [8] (Fig. 3).
3.4. Effect of somatic mutations in aging tissues
It is around 25 years since the ﬁrst observation in aged human heart
andmuscle tissue of a mosaic pattern of impaired cytochrome c oxidase
(COX) function [45,46]. High levels of clonally expanded mtDNA dele-
tions and point mutations were increased within these COX deﬁcient
cells and hypothesized to account for the observed biochemical defect
[47]. The accumulation of mtDNA mutations to levels sufﬁcient to im-
pair mitochondrial respiratory chain function is often termed the ‘bio-
chemical threshold effect’ [Reviewed [48,49]], which describes the
hypothesized situation when wild-type molecules cannot compensate
for mutant mtDNA molecules within the cell. There are however many
complexities within these assumptions which should be discussed in
the context of aging and neurodegenerative disease.
Most studies looking at the association between mtDNA mutations
and mitochondrial function have used either mitochondrial complex
subunit expression [50,51], complex activity [51,52], overall ATP syn-
thesis/oxidative phosphorylation activity [53,54] or clinical phenotype
[17] as their clinical or biochemical end point or ‘threshold’. Using any
of these parameters it is apparent that high levels of heteroplasmy are
needed to impair function, generally in the order of 60–90% of mtDNA
molecules in the single cell setting.
There are several reasons why such high degrees of heteroplasmy
are tolerated before an alteration in cellular activity is seen [48]:
(a) Firstly, there is disproportionate transcriptional activity of mito-
chondria DNA.Whilst mutations in structural complex subunit genes
give rise to a proportionate number of mutated mRNA molecules
[55], in tRNA genes, a higher degree of heteroplasmy can be tolerated
before an impairment of respiratory chain is reached [56]. Secondly,
mtDNA preserves translation; only once mtDNA mutation occurs at
particularly high levels of heteroplasmy does a reduction in protein
translation occur [51]. Thirdly, even in spite of decreased subunit ex-
pression, mitochondrial enzymatic activity can remain normal [51].
Fourthly, the mitochondrial respiratory chain can conserve ATP syn-
thesis and overall oxidative phosphorylation even when the impair-
ment of the activity of one complex occurs [53,54]. This may occur
through changes in respiratory chain organization, composition or
content [48].
4. mtDNA mutations in aging brain
4.1. Deletions
Prior to the detection of mtDNA deletions within the aging brain,
mtDNA deletions were detected in human cardiomyocytes [57,58],
liver [59], and skeletal muscle [57,60]. In the original studies performed
in cardiomyocytes, three main mtDNA deletion sizes were noted; a
4977 base pair deletion (mtDNA4977) [57] termed the ‘common mito-
chondrial DNA deletion’ which has been seen in a variety of aging tis-
sues [61], a 7436 base pair deletion (mtDNA7436) [58] and a larger
10,422 base pair deletion (mtDNA10,422) [62]. The overall ratio ofmtDNA4977 to total mtDNA was very low (ratio 0.00007) in the heart,
and in the muscle (ratio: 0.0002) [63].
The majority of studies assessing mtDNA deletions in human brain
have utilizedmethods to detect themtDNA4977 deletion, rather than de-
ﬁne the spectrum of deletions. The mtDNA4977 deletion, which occurs
between positions 8470 to 8482 and 13,447 to 13,459 of the mitochon-
drial genome, was ﬁrst discovered as one of the germline mtDNA dele-
tions causing Kearns–Sayre syndrome [64]. This deletion encompasses
ﬁve tRNA genes and seven genes encoding subunits of cytochrome c ox-
idase, complex I andATPases [61]. In the context of germlinemtDNAde-
letion syndromes, the dominant pathological mechanism is likely to be
depletion of tRNA gene products and subsequent impaired translation
[65]. This however, as discussed previously on the cellular level, only oc-
curs when heteroplasmy is greater than ~80% [66] due to compensatory
mechanisms from wild-type mtDNA.
There is now consistent evidence that mtDNA4977 deletion levels, in
healthy aged brain tissue homogenate, are consistently less than ~ 2.5%
[61,62,67–69] (Fig. 4). Whilst these levels are low, they are signiﬁcantly
higher than those seen in heart and muscle [63]. In addition, many of
these studies have used tissue samples from different regions of the
brain, and there appears to be evidence of an association between
mtDNA4977 deletion levels and anatomical location (Fig. 4). For example
mtDNA4977 deletion levelswere as high as 2.9% in the substantia nigra of
elderly individuals [68], but consistently lower in the frontal cortex
(mean = 0.2%) [68], temporal cortex (mean = 0.0092%) [70], and cer-
ebellum (mean b0.001%) [67,69]. The lack of evidence supporting the
presence ofmtDNA deletions in human fetal brain suggests that thema-
jority of deletions are likely to be de novo eventswith subsequent clonal
expansion [61].
To date, relatively few studies have systemically sought to detect
non-mtDNA4977 deletions in brain tissue homogenate. Isolated case re-
ports such as that by Corral-Debrinski et al. showed the presence of
mtDNA7436 in the putamen, and frontal and temporal cortex of an
85 year old control individual which were not seen in a 24 year old
[67], suggesting that both mtDNA load and type may vary between
different brain regions over time. Such variation may be explained by
regional differences in mtDNA repair activity throughout the brain as
observed in mice [71], though this ﬁnding has not yet, to our knowl-
edge, been reproduced in humans.
There is also accumulating evidence that ostensibly healthy aged tis-
sues may show unique patterns of mtDNA deletions compared to those
seen in neurodegenerative disease such as PD and AD. A recent meta-
analysis of mtDNA deletions (complied from blood, brain tissue, muscle
and single cell studies) showed that around 5% of D-loop removing de-
letions and 20% of origin of L-strand replication (OL) deletions described
occur in healthy tissues, and over 20% of such deletions have a 3′
breakpoint between bases 16,001–16,100 [72]. In contrast, no mtDNA
deletions removing part of the D-loop, or the OL have been observed
in Parkinson's disease.
It should also be noted that comprehensive assessment of the exact
nature of breakpoints and their levels undertaken within these studies
used a variety of techniques. It is hoped that incremental improvements
in the ability to detect deletion break points will help understand to un-
derstand both the mechanism of formation, and the inter-relationship
betweenmtDNAmutations and the development of neurodegenerative
disorders in coming years.
4.2. Substantia Nigra (SN) deletions
The detection of particularly high levels ofmtDNAdeletions in tissue
homogenate from the SN [67,69] (Fig. 4) lead to several single cell se-
quencing studies in both aged individuals and in PD. In aged control in-
dividuals (n = 5, mean age 82), substantia nigral neurons with normal
COX activity showed high levels of mtDNA deletions (43.3% ± 9.3%)
however, even greater degrees of mtDNA deletions were observed in
COX deﬁcient neurons in the same region (66.9% ± 19%, p b 0.00001)
Fig. 4. Regional variation of the mtDNA4977 deletion in brain. A summary of published studies quantifyingmtDNA4977 mutation ratios and frequencies within control human brain tissue.
Either mtDNA frequency (mean and standard deviation (SD)) or mean mtDNA deletion:wild-type mtDNA ratio are shown and as published or able to be calculated from published data.
Key: H = homogenate and S = single cell.
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deletions were seen within each neuron indicative of clonal expansion.
In comparison, hippocampal neurons had lower deletion levels of
14.3%±6.7% suggestive again of a regional predilection for deletion for-
mation [3]. In parallel, a separate study also showed an age associated
increase in mtDNA deletions in substantia nigral neurons, with many
exceeding 80% heteroplasmy and resulting in 30% of cells becoming
COX deﬁcient [73]. Taken together these data imply that the SN is par-
ticularly vulnerable tomtDNA deletion formation, inducing impairment
of the respiratory chain in up to 30% of cells in normal aging.
A subsequent analysis of deletion break points in aged control SN
neurons (mean age 78.4, n= 5) revealed 19 differing deletions ranging
from 1763 bp to 9445 bp in size. Deletion break point analysis from SN
neurons in patientswith PD, showed no difference between any param-
eter of break point type compared to controls (direct repeat vs no re-
peat, perfect vs imperfect repeat, and overall repeat length) [74].
These ﬁndings suggest that a ubiquitous mechanism exists within the
SN causingmtDNA deletions in both in aging and PD, though the reason
for the generation of such a high level of deletions remains unknown.4.3. Cell type speciﬁc deletions
Themajority of humanbrain tissue studies have utilized either tissue
homogenates, or single cell sequencing of neurons, and there has been a
paucity of studies quantifying mtDNA deletions in non-neuronal cell
typeswithin the brain. Reliable data on deletion levelswithin glia, oligo-
dendrocytes and astrocytes remain unknown. It is likely that such data
would be informative in understanding the contribution of mtDNA de-
letions to neural aging.4.4. Point mutations in aging brain
Initial studies sequencing mtDNA to detect point mutations in the
aging brain utilized tissue homogenates, and focused on the mtDNA
control region (Fig. 2), failing to observe any evidence of heteroplasmic
mutations to the limit of their detection threshold (~20% heteroplasmy)
[75]. Subsequently, studies employing PCR-cloning and Sanger se-
quencing techniques focused speciﬁcally on the T414G mtDNA muta-
tion which had been detected in aged control ﬁbroblast-derived cell
lines [76]. The authors failed to show the accumulation of this variant
in the frontal, occipital, or temporoparietal cortex [77], though did de-
tect 9 different rare pointmutationswithin individual clones suggestive
of the accumulation of multiple low level variants [77].
Subsequently, the notion of an age related increase in low level
heteroplasmic point mutations was conﬁrmed; in 24 control sub-
jects (age N 53, n = 10; age b 31, n = 14) the mtDNA point muta-
tion rate of the primary occipital cortex and temporoparietal or
prefrontal polymodal association cortex was estimated to be
1.75 × 10−4 mutations/bp after correction for PCR error in the
older age group, which was signiﬁcantly higher than young sub-
jects (p = 0.0056) [78]. Most detected mutations were transitions
(88%) in comparison to transversions (10%) and 3% deletions. In-
triguingly, 58% of mutations were protein altering, suggesting
that multiple low level protein altering variants may combine to
cause respiratory chain impairment with age.
More recently massively parallel sequencing has begun to deﬁne in
greater detail the spectra of point mutations with age. A recent study
by Kennedy et al. analyzing mtDNA from the prefrontal cortex of
young (1 year) and old (N75 years) control cases, showedmarkedly dif-
ferent point mutation rates (3.7 ± 0.9 × 10−6 vs 1.9 ± 0.2 × 10−5
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were transitions, with G → A/C → T most common, which were
suggested to be driven by deamination of cytosine to uracil or
misincorporation by DNA polymerase-γ [79,80]. With age, there was
also an increase in the proportion of non-synonymous mutations, and
variants with predicted in silico pathogenicity [79]. Interestingly, al-
though more mutations were seen in the D-loop in both young and
old samples, the relative proportion remained the same in both groups,
suggestive of an age related homogenous accumulation of mtDNA mu-
tations [79].
Other studies using next generation sequencing in human brain
have suggested that somatic mutations occur at 4.02 ± 1.81 × 10−7
per year, corresponding to a 2.6-fold increase in pointmutation rate be-
tween 25 and 80 years of age [81]. The spectra of these mutations were
again 90% transitions, with a skew towards pathogenic SNVs in coding
regions over time [81]. Taken together, these studies suggest that
mtDNA point mutations occur at a low rate, and increase across the
mtDNA genome with age. The overall mutation burden remains lower
than mtDNA deletions.
4.5. Cellular speciﬁcity
Similar to mtDNA deletions, mtDNA point mutations have rarely
been quantiﬁed in non-neural cell types within the brain. Using PCR-
cloning techniques, Cantuti-Castelvetri et al. showed that substantia ni-
gral glia have a lower point mutation rate than neurons from the same
region (133.8 mutations/106 bases vs 200.3 mutations/106 bases) [82].
This was extrapolated by the authors to suggest that each glial and neu-
ronal mitochondrial genome contains a mean of 2.2 (95% CI: 1.6–3.1)
and 3.3 (95% CI: 2.5–4.3) mutations respectively. In keeping with the
ﬁndings from recent next generation sequencing studies, mutations
were found throughout the coding and non-coding regions [82].
In another study, the base mutation rate was again estimated to
be similar to the above estimation ~250 mutations/106 bases using
a PCR-cloning approach in SN neurons from elderly (mean age
75.9 years (sd = 12.7)) individuals [83]. These single cell studies
support the ﬁndings of tissue homogenate work; that mtDNA point
mutations are numerous, increase with age, but generally do not ex-
pand individually beyond low levels of heteroplasmy.
4.6. Summary and relevance of somatic mtDNA mutations in neural aging
Studies deﬁning both point mutations and deletions in the human
brain vary markedly in their methodological approach, tissue or cell
type, and region of the brain. However, in spite of this, it appears clear
that mtDNA deletions accumulate with age within the major arc, and
their levels vary markedly, but relatively consistently throughout the
brain. Deletion levels are generally present in less than 1–2% of
mtDNA genomes, and may cause a deﬁciency of the respiratory chain
in a small proportion of cells.
In contrast, point mutations accumulate slowly, with each mito-
chondrial genome potentially accruing 2–3 mutations with age [78],
but they rarely expand beyond very low levels of heteroplasmy. These
mutations show a predilection to accumulate in neurons rather than
glia, are predominantly transitions, and occur throughout the genome.
Studies over coming years should aim to determine whether non-
respiratory chain cellular dysfunction occurs as a consequence of such
mtDNA mutations to gauge their overall contribution to neural aging.
5. mtDNA mutations in neurodegenerative diseases
Given the evidence supporting an accumulation of mtDNA muta-
tions with age, several studies have aimed to determine whether they
also contribute to age related neurodegenerative disorders. Studies
aiming to determine the contribution of inherited germline variants
(predominantly haplogroup associated variants), and somatic variationhave all been undertaken in a variety of neurodegenerative conditions
over the past 20 years. The most commonly studied disorders are
Lewy body disease (LBD) (predominantly Parkinson's Disease) and
Alzheimer's disease, and the contribution of both inherited and somatic
mtDNA variation is starting to become more clear.
6. Lewy body disease
Parkinson's disease is the second most common neurodegenerative
disorder after Alzheimer's disease, affecting around 1% of the population
aged over 60 years of age [84]. The disorder is clinically characterized by
rigidity, tremor, bradykinesia and postural instability [85], and although
neuronal loss occurs in several brain regions, the preferential depletion
of dopaminergic neurons of the substantia nigra pars compacta underlie
the majority of the key motor features [86]. The classical pathological
hallmark of surviving neurons in affected regions is the accumulation
of intracytoplasmic ﬁbrillar alpha-synuclein aggregates called Lewy
Bodies (LB) [87].
6.1. Homoplasmic population variants
There are several levels of evidence implicating inherited mitochon-
drial mtDNA variants in the pathogenesis of Lewy body diseases. In ad-
dition to the association between mitochondrial DNA haplogroups and
the development of PD, several nuclear DNA mutations which cause
PD occur in genes coding for mitochondrial proteins or are involved in
mitochondrial maintenance (e.g. PARK2 [88], PINK1 [89] and DJ-1 [90]).
However, the original association between mitochondria and PD
began in the 1980s following the development of Parkinsonism in sev-
eral individuals taking the illicit substance N-methyl-1-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP); a potent inhibitor of Complex I of
the mitochondrial respiratory chain [91,92]. Subsequently, in the late
1980s and early 1990s several studies reported impairment of complex
I function in ostensibly idiopathic cases of Parkinson's disease, both in
the substantia nigra [93], platelets [94], ﬁbroblasts [95], muscle [96]
and lymphocytes [97]. However, it should be noted that some authors
only found complex I abnormalities in the brain [98] and normal mito-
chondrial function in non-neural tissues [99,100]. These inconsistencies
were suggested to bedue to variations in the respiratory chainmeasure-
mentmethodologies between studies [101], though the anatomic distri-
bution and degree of mitochondrial dysfunction in sporadic PD remains
difﬁcult to clearly deﬁne.
The rationale that the observed complex I deﬁciency resulted from
abnormalities in mtDNA was born largely from the ﬁndings of ‘cybrid’
studies, in which the contents of a non-nucleated cell are mixed with
those of a nucleated cell resulting in the ability to ‘transfer’ mtDNA
fromone cell into the cytoplasm of another [102]. MtDNA fromplatelets
taken fromPDpatientswas transferred into a cell line depleted of native
mtDNA, andmitochondrial complex I activitywas determined to be 80%
of that of the control cybrid group [103]. Sequencing of mitochondrial
DNA failed to show any variants in complex I genes and the functional
deﬁciency of complex Iwas therefore speculated to be caused by several
low level heteroplasmic variants whichwere present under the existing
threshold for detection.
Whilst it should be noted that a complex I deﬁciency has not been
consistently replicated in all cybrid cell lines [104], these initial studies
suggested the association between low level heteroplasmicmtDNA var-
iants and PD which has spawned many subsequent studies in the ﬁeld.
Over the last 5–10 years, interest has moved into trying to more ac-
curately deﬁne homoplasmic population variants in associationwith PD
primarily through haplogroup association studies. Until recently, sever-
al small-scale haplogroup association studies had shown variable and
inconsistent associations. A recent meta-analysis has clariﬁed many of
these ﬁndings, and identiﬁed both protective and risk haplogroup spe-
ciﬁc alleles associated with Parkinson's disease [105]. In a study of over
3000 cases and 5000 controls, two variants, m.2158TNC inMTRNR2 16s
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phylogenetically linked and deﬁne the mitochondrial super-
haplogroup JT and sub-haplogroup J1b respectively were associated
with a reduced risk of PD (OR = 0.87, 95% CI = 0.77–0.97) [105]. In-
terestingly, the MTRNR2 gene shows 99% sequence homology to
Humanin which has previously been shown to suppress neurotoxic
effects of Alzheimer's disease [106], and therefore whether the pro-
tective effective are mediated by this interaction, or through another
mechanism is unclear. A further analysis by combining data from 10
previous PD studies also showed independent protective effects for
haplogroups J, K and T, and an increased risk of disease for super-
haplogroup HV (p = 3.63 × 10−3, OR = 1.112), though the mecha-
nism remains unclear [105].
6.2. Heteroplasmic variants
The observation of a mosaic pattern of respiratory chain deﬁciency
in human PD post-mortem brain tissue [107] further supported the hy-
pothesis that mitochondrial DNAmutationsmay be implicated in respi-
ratory chain impairment in PD. In 2006 Bender et al. conﬁrmed that PD
patients had a greater proportion of COX deﬁcient neurons in the
substantia nigra than controls (~3% vs 1%, p = 0.003) [3], and although
mtDNA deletion levels in both PD and controls was high in SN tissue ho-
mogenates (52.3% ± 9.3% vs 43.3% ± 9.3%) this did not reach statistical
signiﬁcance (p = 0.06). Using single cell real time PCR, they showed
that mtDNA deletion levels were higher in the COX-deﬁcient neurons
than those with normal COX activity (66.9% ± 19% vs 47.7% ± 24%,
p b 0.00001) underlying their respiratory chain defect. Subsequently
using PCR cloning techniques within both COX deﬁcient and non COX
deﬁcient cells, they detected discrete break points in mtDNA implying
intracellular clonal expansion as the underlyingmechanisms of deletion
formation [3]. Intriguingly, in the hippocampus, a region with relatively
sparse Lewy body deposition, patients also had signiﬁcantly higher de-
letion levels than controls (17.8% ± 12.9% vs 14.3% ± 6.7%, p =
0.0002). Taken together, these data imply that mtDNA deletions are
higher in PD patients, possibly throughout the brain, somatically gener-
ated, and clonally expand in some cases to levels able to cause COX de-
ﬁciency. Whilst this may imply that these deletions contribute to the
pathophysiology of PD, this actually remains unproven. The presence
of mtDNA deletions in the substantia nigra, rather than being deleteri-
ous, may actually trigger adaptive mechanisms such as an increase
mtDNA copy number, improved respiration and greater striatal dopa-
mine levels [108]. Additionally, there is relatively little evidence to sup-
port the notion that mitochondrial respiratory chain deﬁciency
promotes Lewy body formation. At least 2 studies have shown that RC
complex activity (as determined by protein complex expression) is nor-
mal in Lewy body positive cells [109,110].
Over the past 5 years, at least 2 studies have shown that mtDNA
mutations, independent of mitochondrial respiratory chain function,
correlate with Lewy body formation, suggesting that they may be in-
volved in Lewy body formation. In 2012, Lin et al. used cloned-PCR of
single cells to show that mean somatic mtDNA point mutations in
neurons were 250 mutations/106 bp higher in early PD and inciden-
tal Lewy body disease (a presumed precursor to PD) compared to
both controls and late stage disease [83]. They found no difference
between point mutations in established PD and controls. This sug-
gests that mtDNA point mutations may predispose to the early prop-
agation of Lewy bodies, potentially predisposing these neurons to
early cell death enabling the subsequent survival of neurons without
mtDNA mutations. More recently, LB positive neurons were shown
to have greater levels of mtDNA deletions than LB negative neurons
in post mortem cases (40.5 ± 16.8% vs 31.8 ± 14.3%, p b 0.05)
[110]. However, the majority of both LB positive and negative cells
had similar deletion levels, arguing against causality, but implying
that they may confer an alteration in susceptibility to LB develop-
ment, though the mechanism remains unclear.7. Alzheimer's disease
Several facets of Alzheimer's disease biology implicate mitochondri-
al dysfunction in disease pathogenesis. Similar to PD, the presence of
mosaic respiratory abnormalities in cortical neurons [111,112] together
with the more recent detection of cerebral energy hypometabolism
[113,114] and the physical interaction between β-amyloid and mito-
chondria [115], are all suggestive of mitochondrial dysfunction. With
speciﬁc reference to themitochondrial respiratory chain,mitochondrial
complex IV activity has been shown to be decreased in AD cortical
tissue [116,117], and is thought to be a signiﬁcant mediator of the
hypometabolism seen in AD brains.7.1. Homoplasmic population variants
The largest mtDNA haplogroup study in Alzheimer's disease com-
prised over 3000 cases, and failed to show any association between
mitochondrial haplogroups and the development of AD [118]. A subse-
quent analysis of just over 1000 cases which utilized a greater number
of SNPs than many previous studies, suggested that haplogroup
H6A1A andH6A1B conferred a reduction in susceptibility to developing
AD (p=0.016) [27]. This study however conﬂictswith previous smaller
studies which showed that both haplogroups H5 [119] and HV in-
creased risk for the development of AD [120]. Therefore, the evidence
for an association betweenmitochondrial haplogroups and AD remains
inconsistent.
Rare homoplasmic variants have also been suggested to be involved
in the development of AD. The evidence for this stems mainly from ep-
idemiological data showing a weak maternal inheritance bias for AD
[121]. Although rare germline point mutations such as the A→ Gmuta-
tion at np 4336 in the tRNAGln gene have been observed in association
with around 5% of AD cases and only extremely rarely in controls
[122,123], this ﬁnding has not been replicated in all cohorts [124,125].7.2. Heteroplasmic variants
Evidence supporting an association for somatic mtDNAmutations in
the development or progression of AD is also lacking. In theﬁrst study of
mtDNA deletions in human AD post mortem brains, Corral-Debrinski
et al. found that in patients who died under the age of 75, levels of the
common mtDNA4977 deletion were 15 times that of controls, but those
that died over the age of 75 had deletion levels 5 times lower than con-
trols [126]. These surprising ﬁndings have not been replicated in subse-
quent studies of either cortical region, hippocampus or cerebellum [127,
128].
In a study of 23 cases of AD and 40 controls, Coskun et al. sequenced
the hypervariable region of themitochondrial genome (np 16,000–100)
from frontal cortex tissue [129]. They detected several heteroplasmic
point mutations within the hypervariable region, with heteroplasmy
levels between 5 and 80%. Many of these variants occurred close to
the initiation site for L-strand transcription (OL), and the subsequent de-
tection of reduced ND6mRNA levels suggested these variants may con-
fer a signiﬁcant functional effect [129]. However, no high frequency
heteroplasmic variants in the hyper-variable region have been detected
in other studies of AD [75], and many of the heteroplasmic variants de-
scribed by Coskun which were speculated to reduce transcription are
frequently seen as commonhomoplasmic variants in the population, re-
ducing the likelihood of pathogenicity [130].
Evidence for the involvement of coding somatic mtDNA mutations
in association with AD is also lacking. Using a PCR-cloning strategy, so-
matic mutations in coding regions of the CO1 gene were detected in AD
brains at an equal frequency to controls [78]. Taken together, at present
there is little evidence to support the role of mtDNA variation in the
pathogenesis of AD.
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8.1. Homoplasmic population variants
The association between ischemic stroke and mitochondrial
haplogroups has also been contentious due to the majority of studies
having been conducted in small, discrete and differing ethnic cohorts.
Several studies suggested a reduced incidence of stroke in association
with haplogroup D4b in Chinese [131], and H1 in Portuguese patients
[132] together with increased risk with haplogroup A in the Japanese
population [133]. However, in the largest cohort to date undertaken in
two independent subpopulations comprising over 1000 cases, and near-
ly 3000 controls, mtDNA sub-haplogroup Kwas protective for Transient
Ischemic Attacks (TIAs) and stroke (OR = 0.54, 95% CI = 0.39–0.75,
p b 0.00001), conferring a 4% (CI = 2.2–5.7) reduction in risk [28]. The
association between mitochondrial dysfunction and both vascular en-
dothelial senescence [134] and atherosclerosis [135] provides a possible
explanation for the association of mtDNA variants and stroke, though a
unifying mechanism involving the K haplogroup still remains unclear.
9. mtDNA variants in other neurodegenerative disorders
9.1. Homoplasmic population variants
Unlike PD or AD in which observable mitochondrial respiratory
chain dysfunction or hypometabolismoccurs, there have been relatively
few biological observations suggestive of mitochondrial dysfunction in
ostensibly sporadic FTD or ALS.
A single study of 700patients and 462 controls failed to showany as-
sociation between mitochondrial haplogroups and ALS [29]. Similarly,
no association was found between 114 patients with FTD and 180 con-
trols [30]. In FTD, there have been few studies suggesting the association
between rare germlinemtDNA variation and disease, other than an iso-
lated case reports of two rare homoplasmic point mutations in a single
case (np 3337–3340, 3316G → A and 3337G → A) [136]. Although
small, there is additionally little biological evidence to suggest mito-
chondrial dysfunction in tau-mediated neurodegenerative disorders
compared to Lewy body diseases.
9.2. Heteroplasmic variants
The evidence supporting a role formtDNAmutations in ALS is slight-
ly stronger but remains controversial. The discovery that mutations in
superoxide dismutase (SOD1), a genewhich functions to destroy super-
oxide radicals in the body, can cause ALS ﬁrst lead to the association be-
tween oxidative stress and ALS [137]. Subsequently, there have been
case reports describing a patient with a mitochondrial complex I out
of frame deletionwhich is likely to have contributed to disease progres-
sion [138], and a large scale mitochondrial genome rearrangement in
the progressive muscular atrophy (PMA) variant of ALS in a single pa-
tient [139]. In addition, an increase in mtDNA4977 ‘common’ deletion
was detected in SOD1 mutant muscle biopsies in 3 cases, with the
highest deletion load present in themost severe case. The authors spec-
ulated that these mutations may contribute to disease progression,
though the highest detected quantity of this deletion was 15%, below
the threshold expected to cause functional impairment [8]. Further
studies are likely to further deﬁne the association betweenmtDNAmu-
tations and both sporadic and monogenic forms of ALS.
Finally, a mosaic mitochondrial respiratory complex deﬁciency in
gray matter neurons has recently been described in Multiple Sclero-
sis (MS) [140]. Subsequent single cell sequencing techniques
showed that the respiratory chain deﬁciencies may be explained by
clonally expanded mtDNA deletions [140]. These ﬁndings lead to
the possibility that neuroinﬂammationmay predispose to the forma-
tion of mtDNA deletions f or expansion, and that these ﬁndings may
contribute to the gray matter neurodegeneration increasinglyappreciated in MS. The notion of inﬂammatory events predisposing
to mtDNA mutations is certainly intriguing and is likely to be further
explored over coming years.
10. Neurodegenerative neuropathology in mitochondrial disease
Mitochondrial diseases are a clinically heterogeneous group of disor-
ders that result from mutations in mitochondrial and nuclear genes
which subsequently alter mitochondrial function. One of the arguments
often levied against mtDNAmutations contributing to the development
of ostensibly sporadic neurodegenerative disease is the lack of observ-
able post-mortem neuropathological features of common neurodegen-
erative disorders in patients with mitochondrial disease. Whilst to our
knowledge there is no evidence of an association between tau, or amy-
loid deposition post mortem in patients with primary or secondary mi-
tochondrial disease, two of ﬁve patients with a mutation in DNA
polymerase gamma (POLG) showed evidence of sparse Lewy body for-
mation in the substantia nigra [141], with the degree of cell loss
(~70%) similar to that observed in PD [141]. Given that Lewy Bodies
do not form in all patients with Parkinson's disease [88], and that
extra-pyramidal features can be observed in POLG patients [142],
these data imply that POLGmutations may lie on a spectrum of clinical
and neuropathological PD.
11. Conclusion
Over the past 20 years, our understanding of the role of both
germline mtDNA variation and somatic mitochondrial DNA mutations
in neural aging and neurodegeneration has advanced signiﬁcantly.
There is now clear evidence supporting the formationmtDNAdeletions,
and mtDNA point mutations with age. These mutations can, in some
cells, expand to heteroplasmic levels causing respiratory chain dysfunc-
tion, though the effect of low-level variants on overall neural function
and survival remains uncertain.
In neurodegenerative disease, evidence supporting germlinemtDNA
variants as a risk factor for PD, together with somatic mtDNAmutations
with Lewy body pathology is certainly compelling, though the mecha-
nisms mitigating this relationship remain unclear. Understanding in
greater detail the role of mtDNA mutations in cellular dysfunction in
these diseases is likely to be of paramount importance in the ﬁeld over
coming years. Finally, understanding the contribution of inherited
low-level variants in the overall burden of mtDNA mutations is vital in
order to understand the heritability of neural aging and degeneration.
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